Clinigen Group PLC (LON:CLIN) insider John Bacon sold 200,000 shares of the business’s stock in a transaction on Friday, November 11th. The stock was sold at an average price of GBX 717 ($8.96), for a total transaction of £1,434,000 ($1,791,604.20).

Shares of Clinigen Group PLC (LON:CLIN) opened at 732.00 on Wednesday. The company has a 50-day moving average of GBX 741.45 and a 200-day moving average of GBX 636.38. The stock’s market capitalization is GBX 838.86 million. Clinigen Group PLC has a 12 month low of GBX 492.75 and a 12 month high of GBX 793.50.

The firm also recently announced a dividend, which will be paid on Friday, November 25th. Stockholders of record on Thursday, November 3rd will be paid a GBX 2.70 ($0.03) dividend. This represents a dividend yield of 0.38%. The ex-dividend date of this dividend is Thursday, November 3rd. This is an increase from Clinigen Group PLC’s previous dividend of $1.30.

A number of brokerages recently commented on CLIN. Peel Hunt reiterated a “buy” rating and set a GBX 1,000 ($12.49) target price on shares of Clinigen Group PLC in a research note on Monday, November 7th. Numis Securities Ltd reiterated a “buy” rating and set a GBX 933 ($11.66) target price on shares of Clinigen Group PLC in a research note on Tuesday, October 25th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 800 ($10.00) target price on shares of Clinigen Group PLC in a research note on Wednesday, September 28th. Finally, N+1 Singer reiterated a “buy” rating and set a GBX 800 ($10.00) target price on shares of Clinigen Group PLC in a research note on Wednesday, September 28th. Five research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of GBX 856.60 ($10.70).

Clinigen Group PLC Company Profile

Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).

Receive News & Stock Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related stocks with our FREE daily email newsletter.